CNMD Clearmind announces positive safety findings for cmnd 100, demonstrating consistent tolerability throughout full dose escalation in par
CNMD Clearmind announces positive safety findings for cmnd 100, demonstrating consistent tolerability throughout full dose escalation in part a of its FDA-regulated clinical trial Clearmind Medicine - all 24 participants successfully complete treatment in part a of cmnd-100 trial - No serious adverse events observed in part a of cmnd-100 trial - Study achieves primary endpoint of safety and tolerability for cmnd-100
CNMD Clearmind announces positive safety findings for cmnd 100, demonstrating consistent tolerability throughout full dose escalation in part a of its FDA-regulated clinical trial Clearmind Medicine - all 24 participants successfully complete treatment in part a of cmnd-100 trial - No serious adverse events observed in part a of cmnd-100 trial - Study achieves primary endpoint of safety and tolerability for cmnd-100